Recovering from Covid-19 may not offer much lasting protection from future infections for those with only mild cases, according to a report that suggests caution regarding so-called herd immunity as well as the durability of vaccines.
The correspondence in the New England Journal of Medicine outlined research on antibodies taken from the blood of 34 patients who had recovered after suffering mainly mild symptoms that didn’t require intensive care. Just two needed supplemental oxygen and received an HIV medication, and none were on a ventilator or getting Gilead Sciences Inc.’s remdesivir.
